Dr. Talpaz is Professor in the Department of Internal Medicine at University of Michigan Health System. He previously served as professor in the department of experimental therapeutics at the University of Texas M.D. Anderson Cancer Center in Houston, and chairman ad interim of the department of bioimmunotherapy at M. D. Anderson. He holds additional responsibilities as a member of administrative committees, medical societies and editorial boards, and is the author or coo-author of numerous medical articles that have appeared in such medical journals as The New England Journal of Medicine, Cancer, the Journal of Clinical Oncology, and Blood. He is board-certified in internal medicine and medical oncology, and a member of the American Society of Hematology and the National Comprehensive Cancer Network Chronic Myelogenous Leukemia Panel.
Dr. Kirkwood is Associate Director of the Division of Medical Oncology at the University of Pittsburgh Cancer Institute, where he has been the Director of the Melanoma Center since 1985. Following his relocation from Yale to the University of Pittsburgh Cancer Institute, his lab was the first to use antibodies, cytokines, interferons, vaccines and adoptive cellular immunotherapy for melanoma.During that time, Dr. Kirkwood’s laboratory also developed the first US FDA approved high-dose interferon treatment for melanoma in 1996.